Catalog No.
FHD47210
Species reactivity
Human
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Target
CD88, C5AR1, C5R1, C5AR, C5a-R, C5aR, C5a anaphylatoxin chemotactic receptor 1, C5a anaphylatoxin chemotactic receptor
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P21730
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA0039
An antibody-dependent cellular phagocytosis-related gene signature predicts survival and response to immunotherapy in stomach adenocarcinoma., PMID:40193680
Structure of Designer Antibody-like Peptides Binding to the Human C5a with Potential to Modulate the C5a Receptor Signaling., PMID:39051153
Functional Analysis of a Novel Complement C5a Receptor 1-Blocking Monoclonal Antibody., PMID:37952515
Avacopan for the treatment of ANCA-associated vasculitis: an update., PMID:36545762
AVACOPAN: A New Adjunctive Therapy for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis., PMID:36469359
Differential expression of immune-regulatory proteins C5AR1, CLEC4A and NLRP3 on peripheral blood mononuclear cells in early-stage non-small cell lung cancer patients., PMID:36323738
Surface Modification of Biodegradable Microparticles with the Novel Host-Derived Immunostimulant CPDI-02 Significantly Increases Short-Term and Long-Term Mucosal and Systemic Antibodies against Encapsulated Protein Antigen in Young Naïve Mice after Respiratory Immunization., PMID:36145590
How the Availability of Anti-C5a Agents Could Change the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis., PMID:35665698
Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19., PMID:35309299
Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices., PMID:34899737
Being an ADVOCATE for People with ANCA Vasculitis., PMID:34083218
Avacopan for the treatment of ANCA-associated vasculitis., PMID:34006155
CD11c+CD88+CD317+ myeloid cells are critical mediators of persistent CNS autoimmunity., PMID:33785592
Avacopan for the Treatment of ANCA-Associated Vasculitis., PMID:33596356
CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01., PMID:33519816
Autoantibodies against C5aR1, C3aR1, CXCR3, and CXCR4 are decreased in primary Sjogren's syndrome., PMID:33446393
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway., PMID:33362783
Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy., PMID:33351779
The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics., PMID:33023856
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis., PMID:32726800
Pre-existing antibody-mediated adverse effects prevent the clinical development of a bacterial anti-inflammatory protein., PMID:32471891
Complement as a Major Inducer of Harmful Events in Infectious Sepsis., PMID:32187106
The Role of Mast Cells in IgE-Independent Lung Diseases., PMID:32086776
Production of a bispecific antibody targeting TNF-α and C5a in Pichia pastoris and its therapeutic potential in rheumatoid arthritis., PMID:32040674
Immunophenotyping monocytes, macrophages and granulocytes in the Pteropodid bat Eonycteris spelaea., PMID:31941952
Low Density Granulocytes in ANCA Vasculitis Are Heterogenous and Hypo-Responsive to Anti-Myeloperoxidase Antibodies., PMID:31781107
PODXL1 promotes metastasis of the pancreatic ductal adenocarcinoma by activating the C5aR/C5a axis from the tumor microenvironment., PMID:31759250
Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis., PMID:30886997
Expression of complement C3, C5, C3aR and C5aR1 genes in resting and activated CD4+ T cells., PMID:30612786
Utility of leucocyte antigens in distinguishing between bacterial and viral infection in children., PMID:30588170
[What's new in dermatological treatment?]., PMID:30583757
IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction., PMID:30258440
No difference in human mast cells derived from peanut allergic versus non-allergic subjects., PMID:29992767
Aptamers that bind to the human complement component receptor hC5aR1 interfere with hC5aR1 interaction to its hC5a ligand., PMID:29981048
Avacopan in the treatment of ANCA-associated vasculitis., PMID:29718732
The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin., PMID:29602515
An unexpected player in Gaucher disease: The multiple roles of complement in disease development., PMID:29478824
Staphylococcus aureus-induced complement activation promotes tissue factor-mediated coagulation., PMID:29437288
Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors., PMID:28952876
Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function., PMID:28697567
Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults., PMID:28630122
New concepts on the therapeutic control of complement anaphylatoxin receptors., PMID:28576324
Vasculitis: A CLEAR argument for targeting complement in ANCA vasculitis., PMID:28529340
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis., PMID:28400446
Neutrophil Receptor Response to Bacterial N-formyl Peptides is Similar in Term Newborn Infants and Adults in Contrast to IL-8., PMID:27606963
Expression of complement C5a receptor and the viability of 4T1 tumor cells following agonist-antagonist treatment., PMID:27461615
Effective suppression of C5a-induced proinflammatory response using anti-human C5a repebody., PMID:27416759
Brief Report: HIV-1 Infection Impairs CD16 and CD35 Mediated Opsonophagocytosis of Mycobacterium tuberculosis by Human Neutrophils., PMID:27258232
Complement system activation in ANCA vasculitis: A translational success story?, PMID:26597208
A Novel Role for the Receptor of the Complement Cleavage Fragment C5a, C5aR1, in CCR5-Mediated Entry of HIV into Macrophages., PMID:26537334
For research use only. Not for human or drug use.
